Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q14CZ8
UPID:
HECAM_HUMAN
Alternative names:
Hepatocyte cell adhesion molecule
Alternative UPACC:
Q14CZ8; Q67IP8; Q6ZWL4; Q8N7I3; Q8ND35
Background:
The Hepatic and glial cell adhesion molecule, also known as the Hepatocyte cell adhesion molecule, plays a crucial role in regulating cell motility and cell-matrix interactions. This protein's ability to inhibit cell growth by suppressing cell proliferation highlights its significance in cellular functions.
Therapeutic significance:
Linked to neurodegenerative disorders such as Leukoencephalopathy, megalencephalic, with subcortical cysts, 2A, and its milder form, Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without impaired intellectual development, understanding the role of Hepatic and glial cell adhesion molecule could open doors to potential therapeutic strategies.